Rocket Pharmaceuticals (RCKT) Intangibles (2022 - 2026)

Rocket Pharmaceuticals has reported Intangibles for 5 years, with the latest figure at $25.2 million in Q1 2026.

• Quarterly Intangibles changed 0.0% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $25.2 million, changed 0.0% from the prior year.
• Intangibles steadied at $25.2 million in Q1 2026 per RCKT's latest filing, from $25.2 million in the prior quarter.
• Over five years, Intangibles peaked at $25.7 million in Q4 2022 and troughed at $25.2 million in Q3 2023.
• A 5-year average of $25.3 million and a median of $25.2 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2023 and 2024: Intangibles dropped 2.23% in 2023, then changed 0.0% in 2024.
• Over 5 years, Intangibles stood at $25.7 million in 2022, then fell by 2.23% to $25.2 million in 2023, then changed by 0.0% to $25.2 million in 2024, then changed by 0.0% to $25.2 million in 2025, then changed by 0.0% to $25.2 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $25.2 million, $25.2 million, and $25.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.